Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 11/20 | 0.53 |
| ▸ | RAF1 | P04049 | 5/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716479 | 0.95 | BRAF (0.54) | SLC2A1BRAFRAF1FLT3RET | |
| SCHEMBL4718677 | 0.94 | BRAF (0.51) | SLC2A1BRAFRAF1FLT3CSF1R | |
| SCHEMBL4716501 | 0.93 | BRAF (0.52) | SLC2A1BRAFRAF1FLT3KDR | |
| SCHEMBL4718600 | 0.92 | FLT3 (0.49) | SLC2A1BRAFRAF1FLT3RET | |
| SCHEMBL4718541 | 0.90 | KDR (0.49) | SLC2A1BRAFRAF1FLT3KDR | |
| SCHEMBL4717170 | 0.89 | BRAF (0.53) | BRAFRAF1 | |
| SCHEMBL4718429 | 0.88 | BRAF (0.54) | BRAFRAF1 | |
| SCHEMBL4715866 | 0.88 | BRAF (0.54) | BRAFRAF1FLT3CSF1R | |
| SCHEMBL4721876 | 0.88 | BRAF (0.49) | SLC2A1BRAFRAF1FLT3RET | |
| SCHEMBL4715251 | 0.87 | FLT3 (0.48) | BRAFRAF1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | SLC2A1 2090/4885BRAF 2001/4885RAF1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.